Recent controversy hasn't hurt brand value for Pfizer, Valeant: report

Plenty of pharma companies saw their brand values drop between 2015 and 2016 as weaker demand for their products wreaked havoc. But not Pfizer ($PFE) and Valeant ($VRX), both of which posted brand valuation increases greater than 30% in this year's Brand Finance ranking. More from FiercePharmaMarketing

Read more on